32
Participants
Start Date
February 16, 2017
Primary Completion Date
March 22, 2018
Study Completion Date
March 22, 2018
GX-I7
Interleukin-7 (IL-7) is T cell growth factor that can be used for treating lymphopenia patients. GX-I7 is a protein drug recombining human IL-7 and hybrid Fc (hyFc). HyFc made by Genexine is composed of hinge-CH2 region of Immunoglobulin D (IgD) and CH2-CH3 region of Immunoglobulin G4 (IgG4). The recombined region is not exposed and each region's characteristics can reduce immunogenicity and improve the efficacy of drug. Consequently, it will be able to treat the patients with lymphopenia in effective ways.
Placebo
This is the placebo of GX-I7 described above.
Chungnam National University Hospital, Daejeon
Yonsei University Health System, Severance Hospital, Seoul
Hallym University Medical Center-Kangnam, Seoul
Korea University Guro Hospital, Seoul
Lead Sponsor
Genexine, Inc.
INDUSTRY